Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham CSF Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Colony-Stimulating Factors

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for selected granulocyte colony-stimulating factors covered under the medical benefit for MassHealth members. It establishes indication, preferred-product failure or contraindication, medical-necessity, dosing, continuation, and approval-duration requirements.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyColony-Stimulating Factors
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJan 4, 202748d
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL and document the applicable indication, preferred-product history, clinical rationale, and dosing.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was created to manage specified colony-stimulating factors under the MassHealth prior authorization program effective January 4, 2027.

    Medical-benefit management was assigned to the listed colony-stimulating factors, while some products are also available through the pharmacy benefit.

    15Named colony-stimulating factor products
    8Filgrastim indication categories
    1 month

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Acute radiation syndrome approval
    3 monthsMost listed indications approval
    1 yearSevere chronic neutropenia approval
    MedicalPrimary benefit

    Covered Products and Therapy Requirements

    Armlupeg, Neulasta Prefilled Syringe, Nyvepria, Stimufend, Udenyca Prefilled Syringe, and Ziextenzo

    Covered products: Armlupeg, Neulasta prefilled syringe, Nyvepria, Stimufend, Udenyca prefilled syringe, and Ziextenzo.

    ONE of the following

    • If the member is new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days, submit medical records documenting that the member is currently receiving treatment with the requested drug. This does not apply when the product is obtained as samples or through a manufacturer's patient assistance program.
    • ALL of the following

      • ONE of the following indications

        • Primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy
        • Acute exposure to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)
      • BOTH of the following

        • Inadequate response, adverse reaction, or contraindication to ALL of the following

          • For members weighing < 45 kg, Neulasta (pegfilgrastim vial)
          • Fulphila (pegfilgrastim-jmdb)
          • Fylnetra (pegfilgrastim-pbbk)
        • Clinical rationale why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents
      • Appropriate dosing

    Neulasta Onpro, Udenyca On-Body Injector, and Udenyca Prefilled Autoinjector

    Covered products: Neulasta Onpro, Udenyca on-body injector, and Udenyca prefilled autoinjector.

    ALL of the following

    • ONE of the following indications

      • Primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy
      • For Udenyca (pegfilgrastim-cbqv prefilled autoinjector), acute exposure to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)
    • ONE of the following supports medical necessity for the requested agent instead of alternative agents available without prior authorization

      • Cognitive impairment
      • Needle phobia

    Rolvedon and Ryzneuta

    Covered products: Rolvedon (eflapegrastim-xnst) and Ryzneuta (efbemalenograstim alfavuxw).

    ALL of the following

    • Indication of primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy
    • Inadequate response or adverse reaction to ONE, or contraindication to BOTH, of the following

      • Fulphila (pegfilgrastim-jmdb)
      • Fylnetra (pegfilgrastim-pbbk)
    • Appropriate dosing

    Filkri, Granix, Neupogen, and Nypozi

    Covered products: Filkri, Granix, Neupogen, and Nypozi.

    ALL of the following

    • ONE of the following indications

      • Acute exposure to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)
      • Primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy
      • Reduced duration of neutropenia and related clinical sequelae (e.g., febrile neutropenia) associated with myeloablative chemotherapy followed by bone marrow transplantation
      • Reduced duration of severe neutropenia following hematopoietic cell transplantation

    Continuation Therapy

    Continuation of therapy requires BOTH of the following:

    BOTH of the following

    • Resubmission by the prescriber for an FDA-approved diagnosis will infer a positive response to therapy
    • Dosing is appropriate

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required — Medical Benefit

    Prior authorization is required for these colony-stimulating factors under the MassHealth UPPL and applies to the medical benefit. Pharmacy-benefit coverage and criteria may differ for products available through the pharmacy benefit.

    • Medical benefit: call 833-895-2611; fax 888-656-6671.
    • Armlupeg, Filkri, Granix, Neulasta prefilled syringe, Neupogen, Nypozi, Nyvepria, Rolvedon, Ryzneuta, Stimufend, Udenyca prefilled autoinjector, Udenyca prefilled syringe, and Ziextenzo are also available through the pharmacy benefit; consult the MassHealth Drug List.
    • Additional class agents may be available through the pharmacy benefit; consult the MassHealth Drug List for coverage and criteria.
    Documentation Required

    New-Member Documentation Pathway

    For members whose coverage effective date is 90 days or less, submit medical records documenting that the member is currently receiving the requested drug. Current treatment must not have been obtained through samples or a manufacturer’s patient assistance program.

    Clinical Background

    Colony-stimulating factors (CSFs) stimulate the proliferation, differentiation, and release of white blood cells and can affect end-cell functions, including phagocytic ability, cellular metabolism associated with respiratory burst, antibody-dependent killing, and cell-surface antigen expression. Granulocyte colony-stimulating factors (G-CSFs) direct these effects toward granulocytes; Neulasta (pegfilgrastim) and its biosimilars are examples. These agents are used in settings involving neutropenia, including chemotherapy, radiation exposure, transplantation, acute myeloid leukemia, chronic neutropenia, and stem-cell mobilization.

    Key Terms

    Colony-stimulating factors
    DefinitionAgents used to stimulate the proliferation, differentiation, and release of white blood cells.
    Additional effectsColony-stimulating factors also affect end-cell functions, including phagocytic ability, cellular metabolism associated with respiratory burst, antibody-dependent killing, and expression of cell surface antigens.
    G-CSFs
    DefinitionGranulocyte colony-stimulating factors (G-CSFs) are colony-stimulating factors whose effects are directed at granulocytes.
    ExampleNeulasta (pegfilgrastim) is a G-CSF.
    Related productsNeulasta biosimilars are examples of G-CSFs.

    Initial Therapy Requirements

    Non-preferred pegfilgrastim prefilled products

    All criteria must be met.

    Non-preferred pegfilgrastim prefilled products: For Armlupeg, Neulasta prefilled syringe, Nyvepria, Stimufend, Udenyca prefilled syringe, or Ziextenzo, the request must have a covered indication, the required preferred-product failure, adverse reaction, or contraindication, clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents, and appropriate dosing.

    For members weighing less than 45 kg, the required preferred products include Neulasta pegfilgrastim vial, Fulphila, and Fylnetra. For members weighing 45 kg or more, the required preferred products are Fulphila and Fylnetra.

    Device and autoinjector products

    All applicable criteria must be met.

    Device and autoinjector products: For Neulasta Onpro, Udenyca on-body injector, or Udenyca prefilled autoinjector, the request must have a covered indication, qualifying administration-related medical necessity, and appropriate dosing. Neulasta Onpro additionally requires inadequate response, adverse reaction, or contraindication to both Udenyca on-body injector and Udenyca prefilled autoinjector, plus clinical rationale explaining why the requested agent is expected to provide a different clinical outcome than the preferred agents.

    Continuation of Therapy

    Continuation of therapy

    Both of the following are required.

    • The prescriber resubmits for an FDA-approved diagnosis, which infers a positive response to therapy.
    • Dosing is appropriate.

    Preferred-Product Sequencing

    StepRequested productsPreferred-product requirementException or additional requirement
    1Armlupeg, Neulasta prefilled syringe, Nyvepria, Stimufend, Udenyca prefilled syringe, or ZiextenzoDocument inadequate response, adverse reaction, or contraindication to Fulphila and Fylnetra.For members weighing less than 45 kg, also document inadequate response, adverse reaction, or contraindication to Neulasta pegfilgrastim vial. Provide clinical rationale explaining why the requested non-preferred product is expected to produce a different clinical outcome, and document appropriate dosing.
    StepRequested productsPreferred-product requirementException or additional requirement
    1Rolvedon or RyzneutaUse Fulphila or Fylnetra before requesting Rolvedon or Ryzneuta.Document inadequate response or adverse reaction to one preferred product, or contraindication to both preferred products. Appropriate dosing is also required.
    StepRequested productsPreferred-product requirementException or additional requirement
    1Filkri, Granix, Neupogen, or NypoziDocument inadequate response, adverse reaction, or contraindication to Nivestym and to both Releuko and Zarxio.The Releuko and Zarxio requirement does not apply when requesting Granix 300 mcg/0.5 mL vial or Neupogen 300 mcg/0.5 mL vial for a dose less than 180 mcg. Provide clinical rationale for a different clinical outcome, use the minimum necessary strength, and document appropriate weight-based dosing.

    Biosimilar and Preferred Comparator Requirements

    Billing Rule

    Use preferred pegfilgrastim comparators first

    For specified non-preferred pegfilgrastim prefilled products, document the required preferred comparator sequence before requesting authorization. Fulphila and Fylnetra are preferred comparators; for members weighing less than 45 kg, Neulasta pegfilgrastim vial must also be addressed.

    • Required failure basis: inadequate response, adverse reaction, or contraindication.
    • Provide clinical rationale for why the requested product is expected to provide a different clinical outcome.
    Billing Rule

    Apply the preferred comparator rule

    For Rolvedon or Ryzneuta, use Fulphila or Fylnetra first unless the applicable exception is documented. Authorization requires inadequate response or adverse reaction to one preferred product, or contraindication to both preferred products.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyColony-Stimulating Factors
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJan 4, 202748d
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL and document the applicable indication, preferred-product history, clinical rationale, and dosing.
    SourceLink
    On This Page
    Covered Products and Therapy RequirementsAuthorization, Documentation, and Denial RisksClinical BackgroundKey TermsInitial Therapy RequirementsContinuation of TherapyPreferred-Product SequencingBiosimilar and Preferred Comparator Requirements
  1. Physical disability
  2. Visual impairment
  3. For Neulasta Onpro, BOTH of the following are required

    • BOTH of the following

      • Inadequate response, adverse reaction, or contraindication to Udenyca (pegfilgrastim-cbqv on-body injector)
      • Inadequate response, adverse reaction, or contraindication to Udenyca (pegfilgrastim-cbqv prefilled autoinjector)
    • Clinical rationale why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents
  4. Appropriate dosing
  5. Reduced time to neutrophil recovery and duration of fever following induction or consolidation chemotherapy for acute myeloid leukemia
  6. Severe chronic neutropenia, including congenital, cyclic, or idiopathic neutropenia
  7. Stem cell mobilization for hematopoietic cell transplantation
  8. Treatment of febrile neutropenia with high risk of infection-related complications
  9. ALL of the following

    • Inadequate response, adverse reaction, or contraindication to Nivestym (filgrastim-aafi)
    • ONE of the following

      • Inadequate response, adverse reaction, or contraindication to Releuko (filgrastim-ayow) and Zarxio (filgrastim-sndz)
      • For Granix (tbo-filgrastim 300 mcg/0.5 mL vial) or Neupogen (filgrastim 300 mcg/0.5 mL vial), the dose will be administered at < 180 mcg
    • Clinical rationale why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents
  10. Requested strength is the minimum strength necessary to administer the requested dose
  11. Appropriate dosing based on weight
    • Include the member’s coverage effective date and records establishing current treatment with the requested product.
    • Records based solely on samples or manufacturer patient assistance programs do not satisfy this pathway.
    Documentation Required

    New-Member Continuation Documentation

    For a new member seeking continuation of an existing regimen, provide current-treatment records with the authorization request so the plan can verify that treatment with the requested drug began before or during the member’s initial coverage period.

    • Coverage effective date must be less than or equal to 90 days.
    • Document the requested drug, current use, and relevant treatment records.
    • Do not rely on treatment received only through samples or a manufacturer’s patient assistance program.
    Step Therapy

    Preferred-Product Sequencing

    Non-preferred products require documentation that preferred agents were unsuccessful or unsuitable and a clinical rationale explaining why the requested product is expected to produce a different clinical outcome.

    • For the applicable pegfilgrastim products, document inadequate response, adverse reaction, or contraindication to all required preferred agents, including Neulasta pegfilgrastim vial for members weighing less than 45 kg, Fulphila, and Fylnetra.
    • For pegfilgrastim products addressed in the policy, document inadequate response or adverse reaction to either Fulphila or Fylnetra, or contraindication to both.
    • For filgrastim products, document inadequate response, adverse reaction, or contraindication to Nivestym, plus either failure/intolerance/contraindication to both Releuko and Zarxio or the applicable low-dose exception for Granix 300 mcg/0.5 mL vial or Neupogen 300 mcg/0.5 mL vial.
    • Submit the clinical rationale and appropriate dosing.
    Step Therapy

    Neulasta Onpro Step Requirement

    Neulasta Onpro requires a documented prior trial or clinical exception involving both preferred Udenyca administration devices, together with a rationale for a different clinical outcome.

    • Document inadequate response, adverse reaction, or contraindication to both Udenyca on-body injector and Udenyca prefilled autoinjector.
    • Explain why Neulasta Onpro is expected to provide a different clinical outcome than the preferred devices.
    • Document appropriate dosing.
    Documentation Required

    Clinical Documentation and Rationale

    The request must include the diagnosis or indication, the relevant preferred-agent history, any contraindication or adverse reaction, and supporting clinical rationale demonstrating medical necessity for the requested product.

    • Covered indications include primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy and, where specified, acute exposure to myelosuppressive radiation causing the hematopoietic subsyndrome of acute radiation syndrome.
    • For filgrastim products, document the applicable indication, preferred-agent response or intolerance, requested strength, and weight-based dosing.
    • For non-preferred products, explain why the requested agent is expected to provide a different clinical outcome than preferred agents.
    Documentation Required

    Administration-Device Medical Necessity

    When requesting an administration device instead of an alternative available without prior authorization, document medical necessity based on a qualifying functional limitation.

    • Document cognitive impairment, needle phobia, physical disability, or visual impairment.
    • For Udenyca prefilled autoinjector, the request must have a qualifying indication and documentation supporting the need for the device instead of available alternatives.
    Denial Risk

    Pegfilgrastim Non-Preferred Product Requirements

    Pegfilgrastim non-preferred products may be denied when the request lacks a covered indication, required preferred-product failure or intolerance, contraindication documentation, clinical rationale, or appropriate dosing.

    • Document primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy; acute radiation syndrome is also an applicable indication where specified.
    • Document inadequate response, adverse reaction, or contraindication to the required preferred pegfilgrastim products.
    • Provide rationale explaining why the requested non-preferred product is expected to provide a different clinical outcome.
    • Requests without appropriate dosing may be denied.
    Denial Risk

    Device and Administration-Related Denial Risks

    Requests for Neulasta Onpro, Udenyca on-body injector, or Udenyca prefilled autoinjector may be denied unless the indication, device-specific medical necessity, preferred-device requirements, and dosing criteria are documented.

    • Neulasta Onpro requires inadequate response, adverse reaction, or contraindication to both Udenyca on-body injector and Udenyca prefilled autoinjector, plus supporting clinical rationale.
    • Udenyca prefilled autoinjector requires a covered indication and documentation of cognitive impairment, needle phobia, physical disability, or visual impairment supporting use instead of alternatives available without prior authorization.
    • Requests lacking appropriate dosing or required device documentation may be denied.
    Denial Risk

    Filgrastim and Long-Acting Agent Requirements

    Filgrastim and other long-acting agent requests may be denied when the applicable indication, preferred-product documentation, minimum necessary strength, or dosing requirements are not met.

    • Filgrastim indications include acute radiation syndrome; chemotherapy-related febrile-neutropenia prophylaxis; neutropenia associated with myeloablative chemotherapy and bone marrow transplantation; hematopoietic cell transplantation; acute myeloid leukemia chemotherapy; severe chronic neutropenia; stem-cell mobilization; and high-risk febrile neutropenia.
    • Document inadequate response, adverse reaction, or contraindication to Nivestym and the applicable Releuko/Zarxio requirement, unless the specified Granix or Neupogen less-than-180-mcg dosing exception applies.
    • The requested strength must be the minimum strength necessary to administer the requested dose, and dosing must be appropriate based on weight.
    • For pegfilgrastim products, document the applicable indication, preferred-product failure/intolerance or contraindication, and appropriate dosing.

    Administration-related medical necessity may be demonstrated by cognitive impairment, needle phobia, physical disability, or visual impairment.

    Rolvedon and Ryzneuta

    All criteria must be met.

    Rolvedon and Ryzneuta: The indication must be primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy; the member must have inadequate response or adverse reaction to one of Fulphila or Fylnetra, or a contraindication to both; and dosing must be appropriate.

    Filgrastim and tbo-filgrastim products

    All criteria must be met.

    Filgrastim and tbo-filgrastim products: For Filkri, Granix, Neupogen, or Nypozi, the request must have a listed indication, the required preferred-product history, clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents, the minimum necessary strength, and appropriate weight-based dosing.

    The required preferred-product history includes inadequate response, adverse reaction, or contraindication to Nivestym and either inadequate response, adverse reaction, or contraindication to both Releuko and Zarxio, or the specified Granix or Neupogen 300 mcg/0.5 mL vial pathway when the dose is less than 180 mcg.

    • The requested indication must be primary or secondary prophylaxis of febrile neutropenia associated with myelosuppressive chemotherapy.
    • Appropriate dosing is also required.
    Billing Rule

    Document Nivestym failure or exception

    Before requesting Filkri, Granix, Neupogen, or Nypozi, document inadequate response, adverse reaction, or contraindication to Nivestym. Also document the applicable response, adverse reaction, or contraindication to both Releuko and Zarxio unless the specified low-dose vial pathway applies.

    • The low-dose vial pathway applies to Granix 300 mcg/0.5 mL vial or Neupogen 300 mcg/0.5 mL vial when the dose will be administered at less than 180 mcg.
    Billing Rule

    Meet the two-product filgrastim requirement

    For non-preferred filgrastim products, document inadequate response, adverse reaction, or contraindication to both Releuko and Zarxio unless the low-dose vial pathway applies. The pathway is limited to Granix 300 mcg/0.5 mL vial or Neupogen 300 mcg/0.5 mL vial when the dose is less than 180 mcg.

    • The requested strength must be the minimum strength necessary to administer the requested dose.
    • Dosing must be appropriate based on weight.